# Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.

> **NCT06826339** · PHASE4 · RECRUITING · sponsor: **Tiger Biosciences, LLC.** · enrollment: 340 (estimated)

## Conditions studied

- Venous Leg Ulcer
- Venous Leg
- Diabetic Foot
- Diabetic Foot Ulcer
- Foot Ulcer, Diabetic
- Ulcer Foot
- Leg Ulcer
- Ulcer Venous
- Ulcer

## Interventions

- **OTHER:** ACApatch™
- **OTHER:** caregraFT™
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT06826339
- **Lead sponsor:** Tiger Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06826339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06826339, "Evaluating Several Cellular, Acellular, and Matrix-like Products (CAMPs) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot and Venous Leg Ulcers.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06826339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*